Genz 29155

Drug Profile

Genz 29155

Alternative Names: Genz29155

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Amides; Benzophenones; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Transplant rejection

Most Recent Events

  • 21 Dec 2016 Discontinued - Phase-I for Multiple sclerosis in USA (PO)
  • 21 Dec 2016 Discontinued - Preclinical for Transplant rejection in USA (PO)
  • 11 Apr 2011 Genz 29155 is available for licensing as of 31 Dec 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top